Diagnosis, course and management of hypersensitivity pneumonitis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F22%3AN0000024" target="_blank" >RIV/00064190:_____/22:N0000024 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1183/16000617.0169-2021" target="_blank" >https://doi.org/10.1183/16000617.0169-2021</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1183/16000617.0169-2021" target="_blank" >10.1183/16000617.0169-2021</a>
Alternative languages
Result language
angličtina
Original language name
Diagnosis, course and management of hypersensitivity pneumonitis
Original language description
Hypersensitivity pneumonitis (HP) is a complex and heterogeneous interstitial lung disease (ILD) that occurs when susceptible individuals develop an exaggerated immune response to an inhaled antigen. In this review, we discuss the latest guidelines for the diagnostic evaluation of patients with suspected HP, the importance of identifying patients with fibrotic and progressive disease, and the evidence supporting the drugs commonly used in the treatment of HP. Differential diagnosis of HP can be challenging and requires a thorough exposure history, multidisciplinary discussion of clinical and radiologic data, and, in some cases, assessment of bronchoalveolar lavage lymphocytosis and histopathologic findings. Patients with HP may be categorised as having non-fibrotic or fibrotic HP. The presence of fibrosis is associated with worse outcomes. A proportion of patients with fibrotic HP develop a progressive phenotype, characterised by worsening fibrosis, decline in lung function and early mortality. There are no established guidelines for the treatment of HP. Antigen avoidance should be implemented wherever possible. Immunosuppressants are commonly used in patients with HP but have not been shown to slow the worsening of fibrotic disease. Nintedanib, a tyrosine kinase inhibitor, has been approved by the US Food and Drug Administration for slowing the progression of chronic fibrosing ILDs with a progressive phenotype, including progressive fibrotic HP. Non-pharmacological interventions, such as oxygen therapy, pulmonary rehabilitation and supportive care, may be important components of the overall care of patients with progressive HP.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30203 - Respiratory systems
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
EUROPEAN RESPIRATORY REVIEW
ISSN
0905-9180
e-ISSN
1600-0617
Volume of the periodical
31
Issue of the periodical within the volume
163
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
Article Number: 210169
UT code for WoS article
000783164100007
EID of the result in the Scopus database
2-s2.0-85124332355